

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY


(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

REC'D 19 MAY 2005

WIPO

PCT

Applicant's or agent's file reference 27909	FOR FURTHER ACTION		See Form PCT/IPEA/416
International application No. PCT/IL04/00453	International filing date (day/month/year) 27 May 2004 (27.05.2004)	Priority date (day/month/year) 27 May 2003 (27.05.2003)	
International Patent Classification (IPC) or national classification and IPC IPC(7): A61K 31/66; C07F 9/02 and US Cl.: 514/114; 558/169, 170, 172.			
Applicant VASCULAR BIOGENICS, LTD			
<p>1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>3</u> sheets, including this cover sheet.</p> <p>3. This report is also accompanied by ANNEXES, comprising:</p> <p>a. <input type="checkbox"/> (sent to the applicant and to the International Bureau) a total of ___ sheets, as follows:</p> <p style="margin-left: 40px;"><input type="checkbox"/> sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).</p> <p style="margin-left: 40px;"><input type="checkbox"/> sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.</p> <p>b. <input type="checkbox"/> (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) _____, containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).</p>			
<p>4. This report contains indications relating to the following items:</p> <p><input checked="" type="checkbox"/> Box No. I Basis of the report</p> <p><input type="checkbox"/> Box No. II Priority</p> <p><input type="checkbox"/> Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p><input type="checkbox"/> Box No. IV Lack of unity of invention</p> <p><input checked="" type="checkbox"/> Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p><input type="checkbox"/> Box No. VI Certain documents cited</p> <p><input type="checkbox"/> Box No. VII Certain defects in the international application</p> <p><input type="checkbox"/> Box No. VIII Certain observations on the international application</p>			
Date of submission of the demand 15 September 2004 (15.09.2004)		Date of completion of this report 09 April 2005 (09.04.2005)	
Name and mailing address of the IPEA/ US Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571)273-8300		Authorized officer Robert Shiao  Telephone No. (571) 272-1600	

Form PCT/IPEA/409 (cover sheet)(January 2004)

Box No. I Basis of the report

1. With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ This report is based on translations from the original language into the following language _____, which is the language of a translation furnished for the purposes of:

- ☐ international search (under Rules 12.3 and 23.1(b))
☐ publication of the international application (under Rule 12.4)
☐ international preliminary examination (under Rules 55.2 and/or 55.3)

2. With regard to the elements of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:

☒ the international application as originally filed/furnished

☒ the description:

pages 1-100 as originally filed/furnished

pages* NONE received by this Authority on _____

pages* NONE received by this Authority on _____

☒ the claims:

pages 101-120 as originally filed/furnished

pages* NONE as amended (together with any statement) under Article 19

pages* NONE received by this Authority on _____

pages* NONE received by this Authority on _____

☒ the drawings:

pages 1/16-16/16 as originally filed/furnished

pages* NONE received by this Authority on _____

pages* NONE received by this Authority on _____

☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.

3. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
☐ the claims, Nos. _____
☐ the drawings, sheets/figs _____
☐ the sequence listing (*specify*): _____
☐ any table(s) related to the sequence listing (*specify*): _____

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(e)).

- ☐ the description, pages _____
☐ the claims, Nos. _____
☐ the drawings, sheets/figs _____
☐ the sequence listing (*specify*): _____
☐ any table(s) related to the sequence listing (*specify*): _____

* If item 4 applies, some or all of those sheets may be marked "superseded."

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/IL04/00453**Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. Statement**

Novelty (N)	Claims <u>52-90</u>	YES
	Claims <u>1-51</u>	NO
Inventive Step (IS)	Claims 1-90 <u>52-90</u>	YES
	Claims NONE <u>1-51</u>	NO
Industrial Applicability (IA)	Claims <u>1-90</u>	YES
	Claims <u>NONE</u>	NO

2. Citations and Explanations (Rule 70.7)

Claims 1-51 lack novelty under PCT Article 33(2) as being anticipated by (1) Watson et al. publication, Journal of Biological Chemistry, 1997, 272(21), 13597-13607; (2) Shaw et al. publication, J. of Clinical Investigation, 2000, 105(12), 1731-1740, also see CAS: 133:162827.

Applicants claim a compound/composition of formula (I) in claim 1 as agents treating inflammatory disease.

Watson et al. disclose a compound, see page 13603, Fig 6A, clearly anticipates the claimed compounds of formula (I), wherein the variable n is 3, the variable B1, B2, or B3 independently represents oxygen (i.e., O); the variable A1 or A2 independently C=O, X1 and X2 represent formula (II), and the variable m is 1 or 15, and the variable Z is W=CR''- when m is 1 of -A2-X2- of formula (I), and W is O, R'' is hydroxy; or Z is hydrogen when m is 15 of -A1-X1- of formula (I), the variable R1, R'1, R2, R3, R'3, Ra, R'a, Rb, or R'b independently represent hydrogen; the variable Y represents phosphoryl choline.

Shaw et al. disclose a compound 3,5,9-trioxa-4-phosphapentacosan-1-aminum, 7-[(1,5-dioxopentyl)oxy]-4-hydroxy-N,N,N-trimethyl-10-oxo, clearly anticipates the claimed compounds of formula (I), wherein the variable n is 3, the variable B1, B2, or B3 independently represents oxygen (i.e., O); the variable A1 or A2 independently C=O, X1 and X2 represent formula (II), and the variable m is 1 or 15, and the variable Z is W=CR''- when m is 1 of -A2-X2- of formula (I), and W is O, R'' is hydrogen; or Z is hydrogen when m is 15 of -A1-X1- of formula (I), the variable R1, R'1, R2, R3, R'3, Ra, R'a, Rb, or R'b independently represent hydrogen; the variable Y represents phosphoryl choline.

Claims 52-90 meet the criteria set out in PCT Article 33(2). Claims 52-90 are not anticipated over the art of record.

Claims 1-90 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.